Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children

NCT01014091 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: GSK pandemic vaccine GSK2340272A

Sponsor

GlaxoSmithKline